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To the Editor In their recently published paper, 
Lizakowski et al.,1 a renowned research group 
that focuses on the renin–angiotensin–aldoste‑
rone system (RAAS) in renal disease, demonstra‑
ted that the dual blockade of the RAAS with dif‑
ferent combinations of drugs had a similar effect 
on several clinical and laboratory parameters in 
patients with nondiabetic proteinuric chronic 
kidney disease (CKD) to that observed for angio‑
tensin II receptor blocker monotherapy. A combi‑
nation of telmisartan with aliskiren led to a mar‑
ked elevation of plasma renin levels (as compa‑
red with telmisartan with perindopril, telmisar‑
tan with eplerenone, or telmisartan in mono‑
therapy), but the increase did not translate into 
worsening of renal function, aggravation of pro‑
teinuria, or urinary loss of transforming growth 
factor β (TGF ‑β), the key mediator and biomarker 
of renal fibrosis. We agree with the authors that 
these data may suggest lack of direct nephroto‑
xicity of renin. The authors pointed to the safe‑
ty of telmisartan with aliskiren in patients with 
nondiabetic proteinuric renal disease and made 
it the key message of the paper, although they 
were cautious to limit their conclusions to ear‑
ly stages of CKD and patients with low cardiova‑
scular morbidity.
This study1 adds new data to our current knowl‑
edge on therapeutic interventions on the RAAS. 
An extremely attractive, from the conceptual 
point of view, dual (or even triple) blockade of 
the RAAS in renal disease did not, however, trans‑
late into patient benefit in large ‑scale prospective 
clinical trials. The authors cited some of those 
“unsuccessful” studies in their paper (Aliskiren 
Trial in Type 2 Diabetes Using Cardio ‑Renal End‑
points [ALTITUDE] and Ongoing Telmisartan 
Alone and in Combination with Ramipril Global 
Endpoint Trial [ONTARGET]).2,3
The renal community has often argued that, 
indeed, trials concerning dual RAAS blockade 
performed to date did not show benefits of this 
therapeutic approach, but in fact they were not 
designed to show renal benefit in carefully se‑
lected patients with well ‑defined renal disease. 
Hence, nephrologists were waiting for the results 
of the Veterans Affairs Nephropathy in Diabetes 
(VA NEPHRON ‑D) study.4 In brief, the trial was 
performed exclusively in proteinuric patients with 
diabetic nephropathy (glomerular filtration rate 
[GFR] ranging from 30 to 89.9 ml/min/1.73 m2, 
with patients equally distributed within the CKD 
stages: 2, 3a, and 3b). Patients were randomized 
to treatment with losartan (50–100 mg) plus pla‑
cebo vs. losartan combined with escalated doses 
of lisinopril (10–20–40 mg). It should be empha‑
sized that the trial incorporated detailed guide‑
lines for investigators on how to proceed with 
subjects with any risk of hyperkalemia (the main 
“acute” threat of using dual RAAS blockade). De‑
spite a precisely defined study group, careful 
methodology, and appropriate safety measures, 
the VA NEPHRON ‑D trial also failed to demon‑
strate any significant benefit from dual block‑
ade of the RAAS in terms of nephroprotection 
and cardiovascular endpoints. As in many pre‑
vious studies in the field, patients treated with 
dual RAAS blockade more frequently developed 
acute kidney injury and significant hyperkalemia.4
We think that a word of caution is needed be‑
fore concluding on the safety of dual RAAS block‑
ade because short ‑term safety of a carefully super‑
vised small ‑size study group may not be reflected 
by large ‑scale, long ‑term clinical trials, or—par‑
ticularly—everyday clinical practice.
The overall sound of the paper of Lizakowski 
et al.1 is still in favor of dual RAAS blockade (al‑
though they acknowledged limitations of this ap‑
proach). However, we wonder whether the stud‑
ies by Lizakowski et al.1 and Fried et al.4 herald 
the end of the “dual‑blockade” era and we can 
now put the nail in the coffin or whether there is 
still place for additional concepts, projects, and 
trials in this interesting research field. The ques‑
tion of whether the results obtained in protein‑
uric diabetic patients with quite advanced CKD 
(the VA NEPHRON ‑D study population) would 
be the same in proteinuric nondiabetic patients 
with early CKD (as in the study by Lizakowski 
et al.)1 still remains open.
For many years, it has been argued that pleio‑
tropic effects of the RAAS blockade are at least 
LETTER TO THE EDITOR
Dual blockade of the renin –angiotensin – 
–aldosterone system in renal disease: 
what is the future?
LETTER TO THE EDITOR Dual blockade of the renin –angiotensin –aldosterone system… 73
as important as blood pressure lowering in pro‑ 
tecting the kidneys. Recent studies have brought 
somewhat opposite conclusions: blood pressure 
control (independent of the drug class) seems to 
be critical for renal outcome, and—even more im‑
portantly—for the overall outcome of patients 
with renal disease (although RAAS ‑blocking 
agents still remain the first ‑choice antihyper‑ 
tensive drugs in this population).5,6
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